iRadimed Corporation

IRMD Healthcare Medical Devices

iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

88.27 1.10 −1.23%
Market cap
$1.1B
P/E
48.5×
Fwd P/E
48.7×
Dividend yield
0.87%
F-score
6/9
Altman Z
55.62
Beneish M
−2.55
Dividend safety
40/100

iRadimed Corporation (IRMD) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, iRadimed Corporation (IRMD) trades at a P/E ratio of 48.5×. Over the past ten years it has ranged from 11.5× (November 2016) to 372× (June 2021); the current reading is higher than 62% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 55.0× 52.89%
FY2024 35.9× 3.38%
FY2023 34.8× 24.53%
FY2022 27.9× (54.68%)
FY2021 61.6× (67.57%)
FY2020 190× 598.89%
FY2019 27.2× (34.42%)
FY2018 41.5× (86.45%)
FY2017 306× 1,757.86%
FY2016 16.5× (59.46%)

Quarterly newest first

Period P/E ratio Change
Jun 2026 52.5× 1.45%
Mar 2026 51.8× (5.84%)
Dec 2025 55.0× 28.98%
Sep 2025 42.6× 16.17%
42 more quarters

Against its own ten years

Low 11.5× High 372×
Ten-year median 40.2×
Current reading's percentile 67

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on IRMD